OCTAPHARMA
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1983-01-01
- Employees
- -
- Market Cap
- -
- Website
- https://www.octapharma.com/
Clinical Trials
72
Trial Phases
5 Phases
Drug Approvals
27
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
- Conditions
- Significant Bleeding RiskVitamin K-Dependent Coagulation Defect
- Interventions
- First Posted Date
- 2024-05-28
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 3574
- Registration Number
- NCT06429787
- Locations
- 🇺🇸
Octapharma Research Site, Boston, Massachusetts, United States
Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 124
- Registration Number
- NCT06361537
- Locations
- 🇺🇦
Octapharma Research Site, Lviv, Ukraine
Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass
- Conditions
- Acquired Antithrombin Deficiency (Heparin Resistance)
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Octapharma AG
- Target Recruit Count
- 58
- Registration Number
- 2023-507560-39-00
- Locations
- 🇦🇹
Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Medical University of Vienna, AKH, Vienna, Austria
🇷🇴Institutul De Urgenta Pentru Boli Cardiovasculare Prof. Dr. C. C. Iliescu, Bucharest, Romania
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
- First Posted Date
- 2023-07-10
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05936580
- Locations
- 🇺🇸
UT Health San Antonio, San Antonio, Texas, United States
🇫🇮Helsinki University Hospital,Coagulation Disorder Unit, Helsinki, Finland
🇫🇷Avenue de la République, Chambray-lès-Tours, France
Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-20
- Lead Sponsor
- Octapharma
- Target Recruit Count
- 28
- Registration Number
- NCT05935358
- Locations
- 🇮🇳
St. John's Medical College Hospital, Bengaluru, India
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇭🇷University Hospital Centre Zagreb, Zagreb, Croatia
- Prev
- 1
- 2
- 3
- 4
- 5
- 14
- Next
News
Octapharma's PANZYGA Shows Mixed Results in Phase 3 PANS Trial, Achieves Significant Secondary Endpoint
Octapharma's phase 3 trial of PANZYGA for pediatric acute-onset neuropsychiatric syndrome (PANS) missed its primary endpoint of reducing obsessive-compulsive symptoms measured by CY-BOCS score.